Slideshow

CV Risk in Rheumatic Disease

Author(s):

Mark L. Fuerst

(1) Inflammatory diseases raise risk of venous thromboembolism; (2) antiphospholipid antibodies play a role in MI; (3) persistent hyperuricemia predicts mortality.

Related Videos
The Evolving Use of Biologics for PsA Care, with Philip Mease, MD
Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Related Content
Jonathan Graf, MD, professor of Medicine, Division of Rheumatology at the University of California, San Francisco
February 12th 2025

Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Copper and Iron Associated With Fibromyalgia Risk
February 11th 2025

Copper and Iron Associated With Fibromyalgia Risk

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Richard Furie, MD | Credit: Northwell Health
February 7th 2025

REGENCY: Obinutuzumab Proves Efficacy in Lupus Nephritis

Patrick Campbell
Digital Cognitive Behavioral Therapy Stanza to be Covered by Highmark Health
February 7th 2025

Digital Cognitive Behavioral Therapy for Fibromyalgia to be Covered by Highmark Health

Victoria Johnson
© 2025 MJH Life Sciences

All rights reserved.